Usmani Sharjeel, Rasheed Rashid, Marafi Fahad, Al Kandari Fareeda
Department of Nuclear Medicine, Kuwait Cancer Control Center, Khaitan, Kuwait.
Jaber Al-Ahmad Molecular Imaging Center, Kuwait City, Kuwait.
Indian J Nucl Med. 2019 Apr-Jun;34(2):173-175. doi: 10.4103/ijnm.IJNM_141_18.
Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed.
纳武单抗是一种免疫检查点抑制剂，是一种人源化抗程序性死亡-1单克隆抗体，用于二线化疗后治疗各种癌症。我们报告了一名23岁复发性IV期霍奇金淋巴瘤男性患者接受纳武单抗治疗的病例。治疗3个月后，他出现了水样腹泻和腹部绞痛。后续的正电子发射断层扫描-计算机断层扫描显示疾病完全代谢缓解；然而，存在肠壁增厚和结肠扩张，伴有相应的氟脱氧葡萄糖摄取增加。这些发现与纳武单抗治疗相关的免疫相关不良事件，即继发性小肠结肠炎有关。如果能及时、正确诊断，这些不良事件可以得到成功治疗。
